Saltar al contenido principal
amavitaRESEARCH

FOR PATIENTS - MIAMI

Tomorrow's Heart Treatments -- Available to You at No Cost, in Miami, Today.

Active cardiovascular studies. Bilingual coordinators (English and Spanish). World-class investigators. All study-related visits, study medication, and procedures at no cost -- many trials also pay for your time and travel. Apply in 60 seconds and we will call you back the same business day.

Same-day callback / $0 study cost / Bilingual EN-ES

Find My Trial (60-second screening)Call (786) 703-5941

Espanol

New guide: What to Expect When You Join a Cardiovascular Clinical Trial →

Are you a referring physician? See our physician info →

Advanced Cardiovascular of Miami catheterization lab
Affiliated Surgery Center

Advanced cardiovascular care in a comfortable, same-day setting

A licensed, Medicare-certified, AAAHC-accredited cardiovascular ASC in Kendall, Miami, affiliated with Amavita Research.

When a study calls for an ASC procedure, patients can access our affiliated cardiovascular ambulatory surgery center in Miami for same-day outpatient care.

9408 SW 87th Ave, Suite 303, Miami, FL 33176

Showing 6 of 6 trials

Phase 2Heart FailureActive — enrolling

Pfizer BRANCH-HF (C4921003) — PF-07328948 in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocol: C4921003

Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.

Sponsor: Pfizer · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with HFpEF (LVEF ≥ 50%)
  • On stable guideline-directed medical therapy
  • Meeting protocol metabolic / biomarker criteria
Apply for this trial
Phase 3HypertensionActive — enrolling

ZENITH — Zilebesiran in Uncontrolled Hypertension

Hypertension with Cardiovascular Risk

Protocol: ALN-AGT01-008

Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.

Sponsor: Alnylam Pharmaceuticals · PI: Dr. William W. O'Neill, MD, FACC

Key Eligibility

  • Adults 18+ with uncontrolled hypertension
  • Established cardiovascular disease or high cardiovascular risk
  • On stable antihypertensive therapy
Apply for this trial
Phase 3Heart FailureActive — enrolling

ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure

Iron-Deficiency Chronic Heart Failure

Protocol: P-Monofer-CHF-02

Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.

Sponsor: Pharmacosmos · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with symptomatic chronic heart failure
  • Confirmed iron deficiency (TSAT <20% or ferritin criteria)
  • Stable on guideline-directed therapy
Apply for this trial
PivotalVascularActive — enrolling

GREAT — Golazo® Peripheral Atherectomy System

Peripheral Artery Disease

Protocol: AVA-CL-5000

The GREAT Trial evaluates the Golazo® Peripheral Atherectomy System for safe and effective atherectomy in patients with peripheral artery disease. Phase: device IDE study.

Sponsor: Avantec Vascular · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults 18+ with symptomatic PAD
  • Rutherford Class 2–4
  • Suitable target lesion on imaging
Apply for this trial
Phase 1/2Heart FailureActive — enrolling

VASA — Heart Failure with Preserved Ejection Fraction

Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocol: VS-041-102

A safety, tolerability, and biomarker trial of VS-041 in participants with Heart Failure with Preserved Ejection Fraction. Amavita Research Services is an enrolling site under Medpace clinical trial agreement, with Dr. Pedro Martinez-Clark as Principal Investigator.

Sponsor: Vasa Therapeutics, Inc. · PI: Pedro Martinez-Clark, MD, FACC

Key Eligibility

  • Adults with HFpEF (LVEF ≥ 50%)
  • Stable on guideline-directed medical therapy
  • Meeting protocol biomarker criteria
Apply for this trial
RegistryHeart FailureActive — start-up

OPEN HF Registry — Impulse Dynamics

Heart failure — cardiac contractility modulation (CCM)

Protocol: OPEN HF

Cardiac contractility modulation (CCM) heart-failure registry. Amavita Research Services, LLC is a start-up site under a CTA executed 19 August 2026.

Sponsor: Impulse Dynamics

Key Eligibility

    Apply for this trial

    Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.

    Have questions before joining a trial?

    Honest answers about safety, payment, time commitment, your rights, and more.

    Read the Patient FAQ

    FAQ

    Frequently Asked Questions

    Common questions from patients exploring clinical trial participation at Amavita Research.

    Asistente de IA, no una persona. Por favor, no incluya información de salud.